Intellia Therapeutics
This role involves leading the development, optimization, and characterization of solid-phase oligonucleotide synthesis, with a focus on scalability and technology transfer. The position requires managing process characterization studies, supporting downstream purification, and ensuring operational execution through documentation and cross-functional collaboration. The ideal candidate will mentor junior staff and drive continuous improvement within the oligonucleotide and lipid process sciences team.
Headquarters
Cambridge, Massachusetts, United States
Company Size
501-1000 employees
Founded
2014
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
1 week ago
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory (NASDAQ:NTLA)
3 days ago
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Intellia Therapeutics.
23% above the average for this role
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
2 weeks ago